Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company and one of the world's largest corporations. The company was founded by Eli Lilly, a pharmaceutical chemist, in 1876, and is now the 10th largest pharmaceutical company in the world. They are committed to creating high-quality medicines that meet real needs, and have a portfolio of products and pipeline of promising new therapies includes treatments for diabetes, cancer, and autoimmune diseases.

72%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on its reporting.

Bias

90%

Examples:

  • The article 'FDA Approves Lilly's Omvoh (mirikizumab) as First-in-Class Treatment for Adults with Moderate to Severe Ulcerative Colitis' is written by Eli Lilly, the company that produces Omvoh, which could lead to a potential bias in favor of the product.

Conflicts of Interest

20%

Examples:

  • The site 'investor.lilly.com' is owned by Eli Lilly and Company, the pharmaceutical company that produces the drug Omvoh (mirikizumab). This could potentially bias the information presented in the article 'FDA Approves Lilly's Omvoh (mirikizumab) as First-in-Class Treatment for Adults with Moderate to Severe Ulcerative Colitis'.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

  • New Drug Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea, Reducing Need for CPAP Devices by 40-50%

    New Drug Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea, Reducing Need for CPAP Devices by 40-50%

    Broke On: Tuesday, 25 June 2024 New clinical trials show that Eli Lilly's tirzepatide injection, used for diabetes and weight loss, significantly reduces sleep disruptions in obstructive sleep apnea patients. Up to 50% of trial participants no longer needed CPAP devices and experienced lower C-reactive protein levels, systolic blood pressure, and an average weight loss of 18%-20%. The SURMOUNT-OSA studies mark a major advancement in OSA treatment.
  • FDA Delays Approval of Experimental Alzheimer's Drug Donanemab, Sparking Concerns Over Safety and Efficacy

    FDA Delays Approval of Experimental Alzheimer's Drug Donanemab, Sparking Concerns Over Safety and Efficacy

    Broke On: Saturday, 09 March 2024 The FDA has delayed regulatory action on donanemab, an experimental Alzheimer's drug designed to attack a sticky substance in the brain known as amyloid beta. Clinical trials have shown that it slows cognitive decline of people in the early stages of the disease. The FDA plans to hold a hearing with external advisers to explore its safety and effectiveness before making any decision on approval.
  • Eli Lilly Reports Strong Fourth-Quarter 2023 Financial Results with Revenue Increasing by 28% and FDA Approval of New Products

    Eli Lilly Reports Strong Fourth-Quarter 2023 Financial Results with Revenue Increasing by 28% and FDA Approval of New Products

    Broke On: Tuesday, 06 February 2024 Eli Lilly reported strong Q4 2023 financial results with revenue increasing by 28%. New Products revenue grew by $1.7 billion to $4.96 billion, led by Mounjaro and Zepbound. Growth Products revenue increased by 5% to $10.53 billion in Q4 2023, led by Verzenio and Jardiance.
  • Eli Lilly Launches New Service for Telehealth Prescriptions of Weight Loss Drugs

    Eli Lilly Launches New Service for Telehealth Prescriptions of Weight Loss Drugs

    Broke On: Friday, 05 January 2024 Eli Lilly has launched an online service called LillyDirect The platform allows patients to receive telehealth prescriptions and direct home delivery of certain medications for obesity, diabetes and migraines This marks a shift in the drug supply chain by a pharmaceutical company into the digital health-care space Some analysts view this move as an opportunity for Lilly to gain market share in weight loss solutions Others are concerned about its potential impact on traditional players like WeightWatchers and other companies that provide online access to prescription weight-loss drugs.

  • FDA Approves Eli Lilly's Omvoh for Ulcerative Colitis Treatment

    Broke On: Thursday, 26 October 2023 The FDA has approved Eli Lilly's Omvoh for the treatment of adults with moderate to severe ulcerative colitis. The approval is based on the results of a Phase 3 clinical trial, LUCENT-1, which showed that Omvoh significantly improved clinical remission and endoscopic response rates compared to placebo. Omvoh comes with a boxed warning about the risk of serious infections, malignancies, and a rare but serious condition that affects the brain.